Long-Term Efficacy and Safety of Aflibercept Intravitreal Injections for the Treatment of Diabetic Macular Edema in Subjects Who Completed the Three Year VISTA-DME Trial
Phase of Trial: Phase IV
Latest Information Update: 30 Sep 2017
At a glance
- Drugs Aflibercept (Primary)
- Indications Diabetic macular oedema
- Focus Adverse reactions; Therapeutic Use
- Acronyms Endurance3
- 30 Sep 2017 Planned End Date changed from 1 Dec 2016 to 1 Dec 2017.
- 30 Sep 2017 Planned primary completion date changed from 1 Dec 2016 to 1 Dec 2017.
- 14 Apr 2016 New trial record